In the article appearing in the February 2024 issue of the Journal of Cardiovascular Pharmacology, entitled “The Role of SGLT2 Inhibitors on Heart Failure Outcomes in Nondiabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials” there was an error in the abstract that read “There were 10.638 nondiabetic patients, with 5316 patients in the SGLT2i group and 5322 in the placebo group included in this meta-analysis.”1

This should be updated to “There were 10,638 nondiabetic patients, with 5316 patients in the SGLT2i group and 5322 in the placebo group included in this meta-analysis.”

1. Kommu S. The role of SGLT2 inhibitors on heart failure outcomes in nondiabetic patients: a systematic review and meta-analysis of randomized controlled trials. J Cardiovasc Pharmacol. 2024;83:158–166.